[go: up one dir, main page]

RU2013145701A - Способ лечения нейротравмы - Google Patents

Способ лечения нейротравмы Download PDF

Info

Publication number
RU2013145701A
RU2013145701A RU2013145701/15A RU2013145701A RU2013145701A RU 2013145701 A RU2013145701 A RU 2013145701A RU 2013145701/15 A RU2013145701/15 A RU 2013145701/15A RU 2013145701 A RU2013145701 A RU 2013145701A RU 2013145701 A RU2013145701 A RU 2013145701A
Authority
RU
Russia
Prior art keywords
vitamin
composition according
esters
composition
fatty acids
Prior art date
Application number
RU2013145701/15A
Other languages
English (en)
Other versions
RU2622999C2 (ru
Inventor
ВИЛЬДЕ Маттеус Корнелис ДЕ
Йоханнес Вильхельмус Кристина СЕЙБЕН
Патрик Йозеф Герардус Хендрикус КАМПХЕЙС
Роберт Йохан Йозеф ХАГЕМАН
Original Assignee
Н.В. Нютрисиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Н.В. Нютрисиа filed Critical Н.В. Нютрисиа
Publication of RU2013145701A publication Critical patent/RU2013145701A/ru
Application granted granted Critical
Publication of RU2622999C2 publication Critical patent/RU2622999C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/003—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Композиция, содержащая:i) один или более из уридина и цитидина, или их солей, фосфатов, ацильных производных или сложных эфиров;ii) липидную фракцию, содержащую по меньшей мере одну из докозагексаеновой кислоты (22:6; DHA), эйкозапентаеновой кислоты (20:5; EPA) и докозапентаеновой кислоты (22:5; DPA) или их сложные эфиры, где липидная фракция содержит менее чем 2 масс.% α-линоленовой кислоты (ALA), в пересчете на массу всех жирных кислот;iii) холин или его соли и сложные эфиры;где указанная композиция дополнительно содержит по меньшей мере один витамин комплекса B;для применения в профилактике или лечении нейротравмы, травматического повреждения мозга, церебрального паралича и повреждения спинного мозга.2. Композиция по п.1 для применения в профилактике или лечении повреждения спинного мозга.3. Композиция по п.1 или 2, где указанная липидная фракция содержит среднецепочечные жирные кислоты (MCT) и где отношение суммарного количества MCT C6:0 + C7:0 + C8:0 к суммарному количеству C9:0 и С10:0 является меньшим, чем 2:1.4. Композиция по п.1 или 2, где указанная липидная фракция содержит менее чем 2 масс.% жирных кислот с менее чем 14 атомами углерода от общей массы жирных кислот.5. Композиция по п.1 или 2, дополнительно содержащая менее чем 25 мг суммарного количества цистина и таурина на 100 мл композиции.6. Композиция по п.1 или 2, где линолевая кислота (LA) присутствует в количестве, меньшем, чем 15 г/100 г жирных кислот.7. Композиция по п.1 или 2, дополнительно содержащая по меньшей мере один витамин B, выбранный из группы витамина В6, витамина В12 и витамина В9 или их эквивалентов, предпочтительно содержащая витамин В6, В9 и В12.8. Композиция по п.1 или 2, где указанная липидная фр�

Claims (17)

1. Композиция, содержащая:
i) один или более из уридина и цитидина, или их солей, фосфатов, ацильных производных или сложных эфиров;
ii) липидную фракцию, содержащую по меньшей мере одну из докозагексаеновой кислоты (22:6; DHA), эйкозапентаеновой кислоты (20:5; EPA) и докозапентаеновой кислоты (22:5; DPA) или их сложные эфиры, где липидная фракция содержит менее чем 2 масс.% α-линоленовой кислоты (ALA), в пересчете на массу всех жирных кислот;
iii) холин или его соли и сложные эфиры;
где указанная композиция дополнительно содержит по меньшей мере один витамин комплекса B;
для применения в профилактике или лечении нейротравмы, травматического повреждения мозга, церебрального паралича и повреждения спинного мозга.
2. Композиция по п.1 для применения в профилактике или лечении повреждения спинного мозга.
3. Композиция по п.1 или 2, где указанная липидная фракция содержит среднецепочечные жирные кислоты (MCT) и где отношение суммарного количества MCT C6:0 + C7:0 + C8:0 к суммарному количеству C9:0 и С10:0 является меньшим, чем 2:1.
4. Композиция по п.1 или 2, где указанная липидная фракция содержит менее чем 2 масс.% жирных кислот с менее чем 14 атомами углерода от общей массы жирных кислот.
5. Композиция по п.1 или 2, дополнительно содержащая менее чем 25 мг суммарного количества цистина и таурина на 100 мл композиции.
6. Композиция по п.1 или 2, где линолевая кислота (LA) присутствует в количестве, меньшем, чем 15 г/100 г жирных кислот.
7. Композиция по п.1 или 2, дополнительно содержащая по меньшей мере один витамин B, выбранный из группы витамина В6, витамина В12 и витамина В9 или их эквивалентов, предпочтительно содержащая витамин В6, В9 и В12.
8. Композиция по п.1 или 2, где указанная липидная фракция содержит от 9 до 300 мг/100 кДж DHA+EPA+DPA, предпочтительно DHA+EPA, в день.
9. Композиция по п.1 или 2, содержащая от 1,5 до 130 мг/100 кДж одного или более из уридина, цитидина или их солей, фосфатов или сложных эфиров, рассчитанная как для уридина и цитидина.
10. Композиция по п.1 или 2, содержащая от 1 до 300 мг/100 кДж холина, или их солей, или сложных эфиров, рассчитанная как для холина.
11. Композиция по п.1 или 2, дополнительно содержащая один или несколько выбранных из группы, состоящей из витамина C или его эквивалентов, витамина Е или его эквивалентов и селена.
12. Композиция по п.1 или 2, дополнительно содержащая по меньшей мере один фосфолипид.
13. Композиция по п.1 или 2, где лекарственное средство предоставлено в виде продукта питания.
14. Композиция по п.1 или 2, где лекарственное средство предоставлено в виде фармацевтического препарата.
15. Композиция по п.1 или 2, которая представляет собой водную жидкую композицию, содержащую, в расчете на 100 мл жидкости:
100-500 мг EPA,
1000-1500 мг DHA,
80-600 мг фосфолипидов,
200-600 мг холина,
400-800 мг UMP (уридинмонофосфата),
20-60 мг витамина E (альфа-TE),
60-100 мг витамина C,
40-80 мкг селена,
1-5 мкг витамина B12,
0,5-2 мг витамина В6 и
200-600 мкг фолиевой кислоты.
16. Набор, включающий:
i) один или более из уридина и цитидина или их солей, фосфатов или сложных эфиров;
ii) липидную фракцию, содержащую по меньшей мере одну из докозагексаеновой кислоты (22:6; DHA), эйкозапентаеновой кислоты (20:5; EPA) и докозапентаеновой кислоты (22:5; DPA) или их сложные эфиры, где липидная фракция содержит менее чем 2 масс.% α-линоленовой кислоты (ALA), в пересчете на массу всех жирных кислот;
iii) холин или его соли и сложные эфиры;
где указанный набор дополнительно содержит по меньшей мере один витамин комплекса B;
для применения в профилактике или лечении нейротравмы, травматического повреждения мозга, церебрального паралича и повреждения спинного мозга.
17. Набор по п.16 для применения в профилактике или лечении повреждения спинного мозга.
RU2013145701A 2011-03-14 2012-03-14 Способ лечения нейротравмы RU2622999C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2011/050176 2011-03-14
PCT/NL2011/050176 WO2012125020A1 (en) 2011-03-14 2011-03-14 Method for treating neurotrauma
PCT/NL2012/050158 WO2012125034A1 (en) 2011-03-14 2012-03-14 Method for treating neurotrauma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017119470A Division RU2749191C2 (ru) 2011-03-14 2012-03-14 Способ лечения нейротравмы

Publications (2)

Publication Number Publication Date
RU2013145701A true RU2013145701A (ru) 2015-04-20
RU2622999C2 RU2622999C2 (ru) 2017-06-21

Family

ID=45928978

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017119470A RU2749191C2 (ru) 2011-03-14 2012-03-14 Способ лечения нейротравмы
RU2013145701A RU2622999C2 (ru) 2011-03-14 2012-03-14 Способ лечения нейротравмы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2017119470A RU2749191C2 (ru) 2011-03-14 2012-03-14 Способ лечения нейротравмы

Country Status (12)

Country Link
US (2) US9579336B2 (ru)
EP (2) EP2685961B1 (ru)
JP (2) JP6022488B2 (ru)
CN (2) CN103533921B (ru)
AU (2) AU2012229649B2 (ru)
BR (2) BR122020000836B1 (ru)
CA (1) CA2830165C (ru)
ES (2) ES3051389T3 (ru)
MX (2) MX2018003636A (ru)
PL (2) PL2685961T3 (ru)
RU (2) RU2749191C2 (ru)
WO (2) WO2012125020A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
CN102823778B (zh) * 2012-09-24 2013-06-26 吴江市田宇生物科技有限公司 一种实验小型猪专用功能性饲料添加剂
US9301966B2 (en) * 2013-01-11 2016-04-05 Mead Johnson Nutrition Company Nutritional compositions containing magnesium threonate and uses thereof
US20140199265A1 (en) * 2013-01-11 2014-07-17 Mead Johnson Nutrition Company Nutritional compositions containing a neurologic component and uses thereof
US20150139972A1 (en) * 2013-11-18 2015-05-21 Gerald Haase Micronutrient Formulation For Concussive Head Injuries
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
CN105828813A (zh) * 2013-12-19 2016-08-03 塔索斯·乔治奥 涉及治疗神经系统损伤的疾病的ω3脂肪酸组合物
WO2015115885A1 (en) 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
DE102015101273A1 (de) * 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
WO2016148561A1 (en) 2015-03-16 2016-09-22 N.V. Nutricia Method for improving bladder function
WO2017069611A1 (en) * 2015-10-23 2017-04-27 N.V. Nutricia Nutritional product for decreasing phenylalanine levels in pku patients
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017155386A1 (en) 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
WO2017155387A1 (en) 2016-03-08 2017-09-14 N.V. Nutricia Method for supporting memory function and/or cognitive function
US20190151343A1 (en) * 2016-04-04 2019-05-23 N.V. Nutricia Method for improving language skills in children with suspected or confirmed cerebral palsy or children at increased risk thereof
PL3439647T3 (pl) 2016-04-04 2023-08-14 N.V. Nutricia Kompozycja do zastosowania w zmniejszaniu lub zapobieganiu ogólnemu opóźnieniu rozwojowemu u dzieci
WO2017213490A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
ES2935859T3 (es) * 2017-06-09 2023-03-13 Nutricia Nv Composición para mejorar la eficacia de un tratamiento con L-DOPA
WO2019013615A1 (en) 2017-07-12 2019-01-17 N.V. Nutricia METHOD OF TREATING TRAUMATIC BRAIN INJURY
WO2019013616A1 (en) * 2017-07-12 2019-01-17 N.V. Nutricia TREATMENT OF TRAUMATIC BRAIN INJURY
WO2019036442A1 (en) * 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY
BR112020003841A2 (pt) * 2017-08-25 2020-09-08 Struct Nutrition, Llc métodos para atenuar uma lesão cerebral relacionada a traumas em um indivíduo e o impacto de impactos repetidos na cabeça no cérebro, e, composição para atenuar lesões no cérebro relacionados a impactos repetidos na cabeça.
JP6650650B2 (ja) 2017-12-21 2020-02-19 国立大学法人大阪大学 神経系疾患治療剤
CN108578367A (zh) * 2018-06-19 2018-09-28 吉林百年汉克制药有限公司 一种胞二磷胆碱注射液药物组合物及其制备方法和应用
BR112021021769A2 (pt) * 2019-05-06 2021-12-28 Ferrer Int Formas de dosagem sólidas farmacêuticas ou nutracêuticas em multicamadas compreendendo derivados de pirimidina e/ou purina e vitaminas b, preparação e usos destes
WO2022094203A1 (en) * 2020-10-30 2022-05-05 The Trustees Of The University Of Pennsylvania Lipid prophylactic brain injury treatment
EP4401580A1 (en) 2021-09-17 2024-07-24 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
EP4547231A1 (en) 2022-07-01 2025-05-07 N.V. Nutricia Nutritional composition for stroke
WO2025003349A1 (en) 2023-06-30 2025-01-02 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6921775B2 (en) * 2001-08-03 2005-07-26 Children's Medical Center Corporation Methods for modulating brain damage
AU2003237379A1 (en) 2002-06-10 2003-12-22 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
CA2579851C (en) * 2004-09-15 2018-09-04 Massachusetts Institute Of Technology Use of uridine for improving cognitive and neurological functions
CN101495490B (zh) * 2005-05-23 2018-05-08 麻省理工学院 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法
BRPI0613274A2 (pt) * 2005-05-23 2009-08-04 Massachusetts Inst Technology composições que contêm pufa e métodos de uso das mesmas
DK1800675T3 (da) 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
KR20160110532A (ko) * 2006-04-25 2016-09-21 칠드런'즈 메디컬 센터 코포레이션 개방창 및 폐쇄창 척수 손상의 치료를 위한 방법 및 조성물
CA2706824C (en) * 2006-05-09 2014-02-04 Medela Holding Ag Fluid collection reservoir
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
HUE037628T2 (hu) 2007-10-04 2018-09-28 Nestec Sa Készítmények és eljárások kognitív funkció javítására
CN105510850A (zh) * 2007-11-02 2016-04-20 麻省理工学院 尿苷饮食添加顺应性方法及其用途
US20110257267A1 (en) * 2009-10-13 2011-10-20 Kevin Hadley Reducing the Risk of Pathological Effects of Traumatic Brain Injury

Also Published As

Publication number Publication date
US20170135975A1 (en) 2017-05-18
CN103533921B (zh) 2017-09-08
PL3251666T3 (pl) 2025-12-15
US20140066397A1 (en) 2014-03-06
ES3051389T3 (en) 2025-12-29
AU2012229649A1 (en) 2013-10-17
BR122020000836B1 (pt) 2021-05-04
JP6196359B2 (ja) 2017-09-13
CN103533921A (zh) 2014-01-22
JP6022488B2 (ja) 2016-11-09
JP2017052760A (ja) 2017-03-16
WO2012125020A1 (en) 2012-09-20
MX355035B (es) 2018-04-02
EP3251666B1 (en) 2025-08-20
AU2012229649B2 (en) 2017-02-16
US10071072B2 (en) 2018-09-11
EP3251666C0 (en) 2025-08-20
MX2018003636A (es) 2022-06-27
AU2012229649A2 (en) 2013-10-24
WO2012125034A1 (en) 2012-09-20
RU2017119470A3 (ru) 2020-09-11
BR112013023298B1 (pt) 2020-09-01
CN106902104A (zh) 2017-06-30
AU2017201766B2 (en) 2018-05-17
CA2830165A1 (en) 2012-09-20
MX2013010600A (es) 2014-02-28
RU2017119470A (ru) 2018-11-08
PL2685961T3 (pl) 2018-12-31
CA2830165C (en) 2019-09-17
US9579336B2 (en) 2017-02-28
RU2749191C2 (ru) 2021-06-07
EP2685961A1 (en) 2014-01-22
EP3251666A1 (en) 2017-12-06
AU2012229649A9 (en) 2017-02-16
JP2014511830A (ja) 2014-05-19
AU2017201766A1 (en) 2017-04-06
EP2685961B1 (en) 2018-06-27
RU2622999C2 (ru) 2017-06-21
BR112013023298A2 (pt) 2017-02-07
ES2687445T3 (es) 2018-10-25

Similar Documents

Publication Publication Date Title
RU2013145701A (ru) Способ лечения нейротравмы
EP2170316B1 (en) Improving memory in subjects with mini-mental state examination of 24-26
RU2014121891A (ru) Улучшение узнавания
WO2010149662A1 (en) Composition comprising omega-7 and/or omega-4 fatty acids
RU2015148931A (ru) Нутритивная композиция для улучшения функции мозга при фенилкетонурии
CN106535881A (zh) 用于评估和治疗或预防受损的血浆极性脂质水平的方法
US9968629B2 (en) Product and method for supporting uridine homeostasis
US6013273A (en) Treatment of endotoxic shock
WO2024003385A1 (en) Nutritional composition for neurodegeneration and neurotrauma
FI3664628T3 (fi) Kalaöljyä ja/tai omega-3-rasvahappoja käsittäviä emulsioita koskevia menetelmiä ja koostumuksia
WO2019013615A1 (en) METHOD OF TREATING TRAUMATIC BRAIN INJURY
WO2015115885A1 (en) Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
EP3426237B1 (en) Method for treating brain atrophy
EP3364962B1 (en) Method for improving recognition and/or working memory in hyperphenylalaninemia and phenylketonuria patients
RU2017134335A (ru) Способ улучшения функции мочевого пузыря
EP3364961A1 (en) Method for improving equilibrioception in healthy individuals and nutritional composition
JP2007217311A (ja) 神経細胞分化誘導剤
FI3426236T3 (fi) Menetelmä muistitoiminnan ja/tai kognitiivisen toiminnan tukemiseksi
Asuku et al. The Role of Omega-3 Fatty Acids in Mental Health
WO2025003349A1 (en) Nutritional composition for neurodegeneration and neurotrauma
EP4090174A1 (en) A nutraceutical formulation
Kohama et al. Supplementation of Parenteral Nutrition with Fish Oil Attenuates LPS-induced Acute Lung Injury in Rats